Apr 08, 2022
Test your knowledge of melanoma and sarcomas with two multiple-choice questions from the ASCO Self-Evaluation Program (ASCO-SEP) on ASCO Education.
ASCO seeks to advance the education of all oncology professionals and ultimately facilitate and support enhanced patient care. The ASCO Oncology Self-Assessment Series on ASCO Connection consists of free case-based multiple-choice practice questions, educational links, and answer rationales. Questions are developed by a group of oncology experts in multiple tumor topic areas. The self-assessment questions are aligned with the American Board of Internal Medicine (ABIM)’s Medical Oncology blueprints and ASCO’s Medical Oncology In-Training Exam (ITE) blueprints.
Review the Education Essentials for Oncology Fellows (EEOF) package, which includes the ASCO Self-Evaluation Program (ASCO-SEP), hosted on ASCO Education for more online education.
Correct answers are listed at the bottom of the page.
Question 1: Melanoma
- Nivolumab with ipilimumab
- Encorafenib with binimetinib
- High-dose interleukin 2 (IL2)
Question 2: Sarcomas
Question 1 Rationale and References
Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomized, phase 3 trial [published correction appears in Lancet Oncol. 2018 Dec;19(12):e668] [published correction appears in Lancet Oncol. 2018 Nov;19(11):e581]. Lancet Oncol. 2018;19(11):1480-92. DOI: https://doi.org/10.1016/S1470-2045(18)30700-9
Weber JS, Gibney G, Sullivan RJ, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomized, phase 2 trial [published correction appears in Lancet Oncol. 2016 Jul;17 (7):e270]. Lancet Oncol. 2016;17(7):943-55. DOI: https://doi.org/10.1016/S1470-2045(16)30126-7
Question 2 Rationale and References
Heinrich MC, Jones RL, von Mehren M, et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial [published correction appears in Lancet Oncol. 2020 Sep;21(9):e418]. Lancet Oncol. 2020;21(7):935-46. DOI: https://doi.org/10.1016/S1470-2045(20)30269-